Natural IgM in immune equilibrium and harnessing their therapeutic potential

Journal of Immunology

Volumn 188, Issue 3, 2012, Pages 939-945

  Kaveri, Srini V ^a,b,c   Silverman, Gregg J ^d   Bayry, Jagadeesh ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD27 ANTIGEN; CD5 ANTIGEN; CD70 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GANGLIOSIDE GM3; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 18; LEUKOSIALIN; NATURAL IMMUNOGLOBULIN M ANTIBODY; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BODY EQUILIBRIUM; DEMYELINATING DISEASE; ENCEPHALOMYELITIS; GRAFT REJECTION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOGLOBULIN STRUCTURE; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFLAMMATION; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN UNFOLDING; SHORT SURVEY; UVEITIS;

ANIMALS; B-LYMPHOCYTES; HOMEOSTASIS; HUMANS; IMMUNOGLOBULIN M; MICE;

EID: 84856568116     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102107     Document Type: Short Survey

References (88)

1. Walport, M. J. 2001. Complement. First of two parts. N. Engl. J. Med. 344: 1058-1066.
2. Dunkelberger, J. R., and W. C. Song. 2010. Complement and its role in innate and adaptive immune responses. Cell Res. 20: 34-50.
3. Shibuya, A., N. Sakamoto, Y. Shimizu, K. Shibuya, M. Osawa, T. Hiroyama, H. J. Eyre, G. R. Sutherland, Y. Endo, T. Fujita, et al. 2000. Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat. Immunol. 1: 441-446.
4. Kaetzel, C. S. 2005. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol. Rev. 206: 83-99. (Pubitemid 41105164)
5. Adachi, T., S. Harumiya, H. Takematsu, Y. Kozutsumi, M. Wabl, M. Fujimoto, and T. F. Tedder. 2011. CD22 serves as a receptor for soluble IgM. Eur. J. Immunol. In press.
6. Kubagawa, H., S. Oka, Y. Kubagawa, I. Torii, E. Takayama, D. W. Kang, G. L. Gartland, L. F. Bertoli, H. Mori, H. Takatsu, et al. 2009. Identity of the elusive IgM Fc receptor (FcmuR) in humans. J. Exp. Med. 206: 2779-2793.
7. Shima, H., H. Takatsu, S. Fukuda, M. Ohmae, K. Hase, H. Kubagawa, J. Y. Wang, and H. Ohno. 2010. Identification of TOSO/FAIM3 as an Fc receptor for IgM. Int. Immunol. 22: 149-156.
8. Vire, B., A. David, and A. Wiestner. 2011. TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation. J. Immunol. 187: 4040-4050.
9. Elkon, K., and P. Casali. 2008. Nature and functions of autoantibodies. Nat. Clin. Pract. Rheumatol. 4: 491-498.
10. Hardy, R. R., and K. Hayakawa. 2001. B cell development pathways. Annu. Rev. Immunol. 19: 595-621. (Pubitemid 32368047)
11. LeBien, T. W., and T. F. Tedder. 2008. B lymphocytes: how they develop and function. Blood 112: 1570-1580.
12. Sidman, C. L., L. D. Shultz, R. R. Hardy, K. Hayakawa, and L. A. Herzenberg. 1986. Production of immunoglobulin isotypes by Ly-1+ B cells in viable motheaten and normal mice. Science 232: 1423-1425. (Pubitemid 16059397)
13. Baumgarth, N. 2011. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat. Rev. Immunol. 11: 34-46.
14. Griffin, D. O., N. E. Holodick, and T. L. Rothstein. 2011. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. J. Exp. Med. 208: 67-80.
15. Morris, D. L., and T. L. Rothstein. 1993. Abnormal transcription factor induction through the surface immunoglobulin M receptor of B-1 lymphocytes. J. Exp. Med. 177: 857-861. (Pubitemid 23104298)
16. Holodick, N. E., J. R. Tumang, and T. L. Rothstein. 2009. Continual signaling is responsible for constitutive ERK phosphorylation in B-1a cells. Mol. Immunol. 46: 3029-3036.
17. Wong, S. C., W. K. Chew, J. E. Tan, A. J. Melendez, F. Francis, and K. P. Lam. 2002. Peritoneal CD5+ B-1 cells have signaling properties similar to tolerant B cells. J. Biol. Chem. 277: 30707-30715. (Pubitemid 34970767)
18. Hayakawa, K., R. R. Hardy, A. M. Stall, L. A. Herzenberg, and L. A. Herzenberg. 1986. Immunoglobulin-bearing B cells reconstitute and maintain the murine Ly-1 B cell lineage. Eur. J. Immunol. 16: 1313-1316. (Pubitemid 17171540)
19. Kantor, A. B., A. M. Stall, S. Adams, K.Watanabe, and L. A. Herzenberg. 1995. De novo development and self-replenishment of B cells. Int. Immunol. 7: 55-68.
20. Düber, S., M. Hafner, M. Krey, S. Lienenklaus, B. Roy, E. Hobeika, M. Reth, T. Buch, A. Waisman, K. Kretschmer, and S. Weiss. 2009. Induction of B-cell development in adult mice reveals the ability of bone marrow to produce B-1a cells. Blood 114: 4960-4967.
21. Holodick, N. E., K. Repetny, X. Zhong, and T. L. Rothstein. 2009. Adult BM generates CD5+ B1 cells containing abundant N-region additions. Eur. J. Immunol. 39: 2383-2394.
22. Ansel, K. M., R. B. Harris, and J. G. Cyster. 2002. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 16: 67-76. (Pubitemid 34143217)
23. Fagarasan, S., N. Watanabe, and T. Honjo. 2000. Generation, expansion, migration and activation of mouse B1 cells. Immunol. Rev. 176: 205-215.
24. Colombo, M. J., G. Sun, and K. R. Alugupalli. 2010. T-cell-independent immune responses do not require CXC ligand 13-mediated B1 cell migration. Infect. Immun. 78: 3950-3956.
25. Heyman, B. 2000. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu. Rev. Immunol. 18: 709-737. (Pubitemid 30365395)
26. Heyman, B., L. Pilström, and M. J. Shulman. 1988. Complement activation is required for IgM-mediated enhancement of the antibody response. J. Exp. Med. 167: 1999-2004.
27. Ochsenbein, A. F., T. Fehr, C. Lutz, M. Suter, F. Brombacher, H. Hengartner, and R. M. Zinkernagel. 1999. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286: 2156-2159. (Pubitemid 129516290)
28. Zhou, Z. H., Y. Zhang, Y. F. Hu, L. M. Wahl, J. O. Cisar, and A. L. Notkins. 2007. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 1: 51-61. (Pubitemid 46506009)
29. Stäger, S., J. Alexander, A. C. Kirby, M. Botto, N. V. Rooijen, D. F. Smith, F. Brombacher, and P. M. Kaye. 2003. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat. Med. 9: 1287-1292. (Pubitemid 37279852)
30. Kohler, H., J. Bayry, A. Nicoletti, and S. V. Kaveri. 2003. Natural autoantibodies as tools to predict the outcome of immune response? Scand. J. Immunol. 58: 285-289. (Pubitemid 37100363)
31. Jayasekera, J. P., E. A. Moseman, and M. C. Carroll. 2007. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J. Virol. 81: 3487-3494. (Pubitemid 46456657)
32. Rapaka, R. R., D. M. Ricks, J. F. Alcorn, K. Chen, S. A. Khader, M. Zheng, S. Plevy, E. Bengtén, and J. K. Kolls. 2010. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J. Exp. Med. 207: 2907-2919.
33. Fernandez Gonzalez, S., J. P. Jayasekera, and M. C. Carroll. 2008. Complement and natural antibody are required in the long-term memory response to influenza virus. Vaccine 26(Suppl 8): I86-I93.
34. Aimanianda, V., J. Haensler, S. Lacroix-Desmazes, S. V. Kaveri, and J. Bayry. 2009. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol. Sci. 30: 287-295.
35. Manderson, A. P., M. Botto, and M. J. Walport. 2004. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22: 431-456. (Pubitemid 38680429)
36. Chen, Y., Y. B. Park, E. Patel, and G. J. Silverman. 2009. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J. Immunol. 182: 6031-6043.
37. Quartier, P., P. K. Potter, M. R. Ehrenstein, M. J. Walport, and M. Botto. 2005. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur. J. Immunol. 35: 252-260. (Pubitemid 40123872)
38. Chen, Y., S. Khanna, C. S. Goodyear, Y. B. Park, E. Raz, S. Thiel, C. Grönwall, J. Vas, D. L. Boyle, M. Corr, et al. 2009. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J. Immunol. 183: 1346-1359.
39. Notley, C. A., M. A. Brown, G. P. Wright, and M. R. Ehrenstein. 2011. Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J. Immunol. 186: 4967-4972.
40. Shaw, P. X., C. S. Goodyear, M. K. Chang, J. L. Witztum, and G. J. Silverman. 2003. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J. Immunol. 170: 6151-6157. (Pubitemid 36682598)
41. Binder, C. J., and G. J. Silverman. 2005. Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin. Immunopathol. 26: 385-404. (Pubitemid 40468892)
42. Pryor, W. A., and J. P. Stanley. 1975. Letter: A suggested mechanism for the production of malonaldehyde during the autoxidation of polyunsaturated fatty acids. Nonenzymatic production of prostaglandin endoperoxides during autoxidation. J. Org. Chem. 40: 3615-3617.
43. Shaw, P. X., S. Hörkkö, M. K. Chang, L. K. Curtiss, W. Palinski, G. J. Silverman, and J. L. Witztum. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
44. Binder, C. J., S. Hörkkö, A. Dewan, M. K. Chang, E. P. Kieu, C. S. Goodyear, P. X. Shaw, W. Palinski, J. L. Witztum, and G. J. Silverman. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9: 736-743. (Pubitemid 36749223)
45. Chang, M. K., C. Bergmark, A. Laurila, S. Hörkkö, K. H. Han, P. Friedman, E. A. Dennis, and J. L. Witztum. 1999. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc. Natl. Acad. Sci. USA 96: 6353-6358. (Pubitemid 29256669)
46. Ehrenstein, M. R., and C. A. Notley. 2010. The importance of natural IgM: scavenger, protector and regulator. Nat. Rev. Immunol. 10: 778-786.
47. Kyaw, T., C. Tay, S. Krishnamurthi, P. Kanellakis, A. Agrotis, P. Tipping, A. Bobik, and B. H. Toh. 2011. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ. Res. 109: 830-840.
48. Karvonen, J., M. Päivänsalo, Y. A. Kesäniemi, and S. Hörkkö. 2003. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108: 2107-2112. (Pubitemid 37337587)
49. Tsimikas, S., E. S. Brilakis, R. J. Lennon, E. R. Miller, J. L. Witztum, J. P. McConnell, K. S. Kornman, and P. B. Berger. 2007. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J. Lipid Res. 48: 425-433. (Pubitemid 46220609)
50. Reardon, C. A., E. R. Miller, L. Blachowicz, J. Lukens, C. J. Binder, J. L. Witztum, and G. S. Getz. 2004. Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice. J. Lipid Res. 45: 1347-1354. (Pubitemid 38802638)
51. Kim, S., K. B. Elkon, and X. Ma. 2004. Transcriptional suppression of interleukin- 12 gene expression following phagocytosis of apoptotic cells. Immunity 21: 643-653. (Pubitemid 39487888)
52. Su, J., X. Hua, H. Concha, E. Svenungsson, A. Cederholm, and J. Frostegård. 2008. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 47: 1144-1150. (Pubitemid 352038217)
53. Anania, C., T. Gustafsson, X. Hua, J. Su, M. Vikström, U. de Faire, M. Heimbürger, T. Jogestrand, and J. Frostegård. 2010. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res. Ther. 12: R214.
54. Mehrani, T., and M. Petri. 2011. IgM anti-b2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J. Rheumatol. 38: 450-453.
55. David, K., M. W. Ollert, C. Vollmert, S. Heiligtag, B. Eickhoff, R. Erttmann, R. Bredehorst, and C. W. Vogel. 1999. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen. Cancer Res. 59: 3768-3775. (Pubitemid 29381885)
56. Schwartz-Albiez, R., S. Laban, S. Eichmüller, and M. Kirschfink. 2008. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? Autoimmun. Rev. 7: 491-495.
57. Rauschert, N., S. Brändlein, E. Holzinger, F. Hensel, H. K. Müller-Hermelink, and H. P. Vollmers. 2008. A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab. Invest. 88: 375-386. (Pubitemid 351432774)
58. Brändlein, S., N. Rauschert, L. Rasche, A. Dreykluft, F. Hensel, E. Conzelmann, H. K. Müller-Hermelink, and H. P. Vollmers. 2007. The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein. Mol. Cancer Ther. 6: 326-333. (Pubitemid 46206697)
59. Ehrenstein, M. R., H. T. Cook, and M. S. Neuberger. 2000. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J. Exp. Med. 191: 1253-1258.
60. Hurez, V., S. V. Kaveri, and M. D. Kazatchkine. 1993. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur. J. Immunol. 23: 783-789. (Pubitemid 23101058)
61. Boes, M., T. Schmidt, K. Linkemann, B. C. Beaudette, A. Marshak-Rothstein, and J. Chen. 2000. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc. Natl. Acad. Sci. USA 97: 1184-1189. (Pubitemid 30080833)
62. Baker, N., and M. R. Ehrenstein. 2002. Cutting edge: selection of B lymphocyte subsets is regulated by natural IgM. J. Immunol. 169: 6686-6690. (Pubitemid 36899252)
63. Taguchi, H., S. Planque, Y. Nishiyama, J. Symersky, S. Boivin, P. Szabo, R. P. Friedland, P. A. Ramsland, A. B. Edmundson, M. E. Weksler, and S. Paul. 2008. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J. Biol. Chem. 283: 4714-4722.
64. Kinoshita, M., N. Shinomiya, S. Ono, H. Tsujimoto, T. Kawabata, A. Matsumoto, H. Hiraide, and S. Seki. 2006. Restoration of natural IgM production from liver B cells by exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas aeruginosa. J. Immunol. 177: 4627-4635. (Pubitemid 44469795)
65. Kuranaga, N., M. Kinoshita, T. Kawabata, Y. Habu, N. Shinomiya, and S. Seki. 2006. Interleukin-18 protects splenectomized mice from lethal Streptococcus pneumoniae sepsis independent of interferon-gamma by inducing IgM production. J. Infect. Dis. 194: 993-1002. (Pubitemid 44454085)
66. Capolunghi, F., S. Cascioli, E. Giorda, M. M. Rosado, A. Plebani, C. Auriti, G. Seganti, R. Zuntini, S. Ferrari, M. Cagliuso, et al. 2008. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J. Immunol. 180: 800-808.
67. Wool, G. D., V. G. Cabana, J. Lukens, P. X. Shaw, C. J. Binder, J. L. Witztum, C. A. Reardon, and G. S. Getz. 2011. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J. 25: 290-300.
68. Pashov, A., G. Canziani, B. Monzavi-Karbassi, S. V. Kaveri, S. Macleod, R. Saha, M. Perry, T. C. Vancott, and T. Kieber-Emmons. 2005. Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens. J. Biol. Chem. 280: 28959-28965. (Pubitemid 41161342)
69. Caligiuri, G., J. Khallou-Laschet, M. Vandaele, A. T. Gaston, S. Delignat, C. Mandet, H. V. Kohler, S. V. Kaveri, and A. Nicoletti. 2007. Phosphorylcholinetargeting immunization reduces atherosclerosis. J. Am. Coll. Cardiol. 50: 540-546.
70. Hernández, A. M., D. Toledo, D. Martínez, T. Griñán, V. Brito, A. Macías, S. Alfonso, T. Rondón, E. Suárez, A. M. Vázquez, and R. Pérez. 2008. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in nonsmall cell lung cancer patients immunized with an anti-idiotype antibody. J. Immunol. 181: 6625-6634.
71. Mulens, V., A. de la Torre, P. Marinello, R. Rodríguez, J. Cardoso, R. Díaz, M. O'Farrill, A. Macias, C. Viada, G. Saurez, et al. 2010. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum. Vaccin. 6: 736-744.
72. Hernández, A. M., N. Rodríguez, J. E. González, E. Reyes, T. Rondón, T. Griñán, A. Macías, S. Alfonso, A. M. Vázquez, and R. Pérez. 2011. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J. Immunol. 186: 3735-3744.
73. Bayry, J., V. S. Negi, and S. V. Kaveri. 2011. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 7: 349-359.
74. Bayry, J., S. Lacroix-Desmazes, M. D. Kazatchkine, and S. V. Kaveri. 2004. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol. Sci. 25: 306-310. (Pubitemid 38692422)
75. Stehr, S. N., L. Knels, C. Weissflog, J. Schober, D. Haufe, A. Lupp, T. Koch, and A. R. Heller. 2008. Effects of IGM-enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia. Shock 29: 167-172.
76. Norrby-Teglund, A., K. N. Haque, and L. Hammarström. 2006. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J. Intern. Med. 260: 509-516. (Pubitemid 44772370)
77. Rieben, R., A. Roos, Y. Muizert, C. Tinguely, A. F. Gerritsen, and M. R. Daha. 1999. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 93: 942-951. (Pubitemid 29067860)
78. Walpen, A. J., T. Laumonier, C. Aebi, P. J. Mohacsi, and R. Rieben. 2004. Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum. Xenotransplantation 11: 141-148. (Pubitemid 38282265)
79. Maddur, M. S., J. Vani, S. Lacroix-Desmazes, S. Kaveri, and J. Bayry. 2010. Autoimmunity as a predisposition for infectious diseases. PLoS Pathog. 6: e1001077.
80. Bieber, M. M., N. M. Bhat, and N. N. Teng. 1995. Anti-endotoxin human monoclonal antibody A6H4C5 (HA-1A) utilizes the VH4.21 gene. Clin. Infect. Dis. 21(Suppl 2): S186-S189.
81. Hurez, V., M. D. Kazatchkine, T. Vassilev, S. Ramanathan, A. Pashov, B. Basuyaux, Y. de Kozak, B. Bellon, and S. V. Kaveri. 1997. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90: 4004-4013. (Pubitemid 27484054)
82. Vassilev, T., M. Yamamoto, A. Aissaoui, E. Bonnin, S. Berrih-Aknin, M. D. Kazatchkine, and S. V. Kaveri. 1999. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur. J. Immunol. 29: 2436-2442. (Pubitemid 29378113)
83. Warrington, A. E., K. Asakura, A. J. Bieber, B. Ciric, V. Van Keulen, S. V. Kaveri, R. A. Kyle, L. R. Pease, and M. Rodriguez. 2000. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 97: 6820-6825. (Pubitemid 30412798)
84. Bieber, A. J., A. Warrington, K. Asakura, B. Ciric, S. V. Kaveri, L. R. Pease, and M. Rodriguez. 2002. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 37: 241-249.
85. Varambally, S., Y. Bar-Dayan, J. Bayry, S. Lacroix-Desmazes, M. Horn, M. Sorel, Y. Bar-Dayan, G. Ruberti, M. D. Kazatchkine, and S. V. Kaveri. 2004. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int. Immunol. 16: 517-524. (Pubitemid 38313160)
86. Vassilev, T., N. Mihaylova, E. Voynova, M. Nikolova, M. Kazatchkine, and S. Kaveri. 2006. IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu- SCID mice. Clin. Exp. Immunol. 145: 108-115. (Pubitemid 43893939)
87. Warrington, A. E., and M. Rodriguez. 2010. Method of identifying natural antibodies for remyelination. J. Clin. Immunol. 30(Suppl 1): S50-S55.
88. Watzlawik, J., E. Holicky, D. D. Edberg, D. L. Marks, A. E. Warrington, B. R. Wright, R. E. Pagano, and M. Rodriguez. 2010. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia 58: 1782-1793.